St. Jude Medical Announces FDA Approval of Current Plus ICD and Promote Plus CRT-D Devices

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of the Promote® Plus cardiac resynchronization therapy defibrillator (CRT-D) and Current® Plus implantable cardioverter defibrillators (ICDs), designed with TailoredTherapy™ features that give physicians more options for customizing therapy for patients with potentially lethal heart arrhythmias and heart failure.

“There is no ‘text book’ patient. Each person presents a unique anatomy, disease state and response to therapy,” said Eric S. Fain, M.D., president of the St. Jude Medical Cardiac Rhythm Management Division. “With the feature set available in the Promote Plus and Current Plus devices, physicians can customize programming to ensure each patient is receiving therapy that is appropriate for his or her individual condition.”

The Promote Plus CRT-D and Current Plus ICDs also offer a smoother header configuration designed to offer better patient comfort and improve visibility at the connector site, where the thin wire (called a lead) that delivers the electricity from the device to the heart is connected.

To better assist physicians in accurately diagnosing and managing patients with fast rates in the heart’s upper chambers (atria), the Promote Plus CRT-D and Current Plus ICDs also include a new atrial tachycardia/atrial fibrillation (AT/AF) Alert feature. This feature is designed to notify physicians when a rapid atrial rate exceeds a programmed value and occurs over an extended time period. These devices can also be programmed to notify the patient through a unique vibratory alert that has been clinically proven more effective than audible alerts.1 Additionally, the devices have the ability to inform the patient’s clinic through the St. Jude Medical Merlin@home® transmitter and™ Patient Care Network (PCN). These features allow the physician to better manage patients’ atrial arrhythmias, such as AF.

The Promote Plus CRT-D and Current Plus ICDs are built on the St. Jude Medical consolidated hardware and software “Unity” device platform and include the company’s advanced safety features and algorithms for better patient management. These include improved lead monitoring capabilities – including daily checks of all pacing and shock configurations – that provide added patient safety.

TailoredTherapy features in these devices include:

  • QuickOpt® timing cycle optimization – a programmer-based optimization method that is proprietary to St. Jude Medical that is used with CRT-Ds, CRT-Ps (cardiac resynchronization therapy pacemakers) and ICDs to help physicians quickly program the device’s timing cycles – in about 90 seconds – to help deliver optimal therapy to patients
  • DeFT Response® technology – designed to help devices meet the needs of patients with high or varying defibrillation thresholds, helping physicians to ensure appropriate delivery of life-saving therapy
  • VIP® (Ventricular Intrinsic Preference) algorithm – provides a delay in device stimulation of the lower chambers of the heart (ventricles) to allow the patient’s own heart rhythm to prevail when possible. The VIP technology is designed to provide device stimulation only when needed, which has been shown to be better for patients’ overall heart health.
  • SenseAbility® technology – designed to enable physicians to program the device to more accurately sense abnormal heart rhythms, thereby protecting the patient from receiving inappropriate shocks

An ICD is a small device implanted in the chest to treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardias or ventricular fibrillation), which often lead to sudden cardiac death (SCD). Nearly 1,000 people every day and more than 350,000 every year in the U.S. die from SCD. An ICD delivers potentially life-saving therapy from the device to the patient’s heart through an insulated wire or lead.

Cardiac resynchronization therapy – delivered in an ICD or a pacemaker – resynchronizes the beating of the heart’s lower chambers (ventricles), which often beat out of sync in heart failure patients. Studies have shown that CRT can improve the quality of life for many patients with heart failure, a progressive condition in which the heart weakens and loses its ability to pump an adequate supply of blood. About 5 million Americans suffer from heart failure, with 550,000 new cases diagnosed every year, according to the American Heart Association.

Source:  St Jude Medical

Share your thoughts

Your email address will not be published. Required fields are marked *